Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

FimH-based display of functional eukaryotic proteins on bacteria surfaces.

Chmielewski M, Kuehle J, Chrobok D, Riet N, Hallek M, Abken H.

Sci Rep. 2019 Jun 10;9(1):8410. doi: 10.1038/s41598-019-44883-z.

2.

CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Bluhm J, Kieback E, Marino SF, Oden F, Westermann J, Chmielewski M, Abken H, Uckert W, Höpken UE, Rehm A.

Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.

PMID:
30078440
3.

Depletion of Collagen IX Alpha1 Impairs Myeloid Cell Function.

Probst K, Stermann J, von Bomhard I, Etich J, Pitzler L, Niehoff A, Bluhm B, Xu HC, Lang PA, Chmielewski M, Abken H, Blissenbach B, Machova A, Papadopoulou N, Brachvogel B.

Stem Cells. 2018 Nov;36(11):1752-1763. doi: 10.1002/stem.2892. Epub 2018 Sep 11.

PMID:
30063808
4.

CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.

Golumba-Nagy V, Kuehle J, Hombach AA, Abken H.

Mol Ther. 2018 Sep 5;26(9):2218-2230. doi: 10.1016/j.ymthe.2018.07.005. Epub 2018 Jul 10.

PMID:
30055872
5.

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.

Köhl U, Arsenieva S, Holzinger A, Abken H.

Hum Gene Ther. 2018 May;29(5):559-568. doi: 10.1089/hum.2017.254. Epub 2018 Apr 5.

PMID:
29620951
6.

Nanobody Based Dual Specific CARs.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E403. doi: 10.3390/ijms19020403.

7.

CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors.

Chmielewski M, Abken H.

Cell Rep. 2017 Dec 12;21(11):3205-3219. doi: 10.1016/j.celrep.2017.11.063.

8.

CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.

Martyniszyn A, Krahl AC, André MC, Hombach AA, Abken H.

Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.

PMID:
29207878
9.

Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma.

Skuljec J, Chmielewski M, Happle C, Habener A, Busse M, Abken H, Hansen G.

Front Immunol. 2017 Sep 12;8:1125. doi: 10.3389/fimmu.2017.01125. eCollection 2017.

10.
11.

Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.

Abken H.

Hum Gene Ther. 2017 Nov;28(11):1047-1060. doi: 10.1089/hum.2017.115. Epub 2017 Aug 15. Review.

PMID:
28810803
12.

Identification of a myofibroblast-specific expression signature in skin wounds.

Bergmeier V, Etich J, Pitzler L, Frie C, Koch M, Fischer M, Rappl G, Abken H, Tomasek JJ, Brachvogel B.

Matrix Biol. 2018 Jan;65:59-74. doi: 10.1016/j.matbio.2017.07.005. Epub 2017 Aug 7.

PMID:
28797711
13.

Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.

Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4.

14.

CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.

Holzinger A, Abken H.

Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28. No abstract available.

PMID:
28755091
15.

Genetic Modification of T Cells with Chimeric Antigen Receptors: A Laboratory Manual.

Golumba-Nagy V, Kuehle J, Abken H.

Hum Gene Ther Methods. 2017 Dec;28(6):302-309. doi: 10.1089/hgtb.2017.083. Epub 2017 Jul 24.

PMID:
28741380
16.

STRIP2 Is Indispensable for the Onset of Embryonic Stem Cell Differentiation.

Sabour D, Srinivasan SP, Rohani S, Wagh V, Gaspar JA, Panek D, Ardestani MA, Doss MX, Riet N, Abken H, Hescheler J, Papadopoulos S, Sachinidis A.

Mol Ther Methods Clin Dev. 2017 Apr 14;5:116-129. doi: 10.1016/j.omtm.2017.04.001. eCollection 2017 Jun 16.

17.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

18.

Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology<sup/>.

Herling M, Rengstl B, Scholtysik R, Hartmann S, Küppers R, Hansmann ML, Diebner HH, Roeder I, Abken H, Newrzela S, Kirberg J.

Leuk Lymphoma. 2017 Apr;58(4):788-796. doi: 10.1080/10428194.2016.1222381. Epub 2016 Sep 19.

PMID:
27643643
19.

The growing world of CAR T cell trials: a systematic review.

Holzinger A, Barden M, Abken H.

Cancer Immunol Immunother. 2016 Dec;65(12):1433-1450. Epub 2016 Sep 9. Review.

PMID:
27613725
20.

Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?

Hombach AA, Abken H.

Expert Rev Clin Immunol. 2017 Feb;13(2):151-155. doi: 10.1080/1744666X.2016.1221763. Epub 2016 Aug 22. Review.

PMID:
27546707

Supplemental Content

Loading ...
Support Center